HJCC has released its next-generation genetically modified mouse platform, AlivaMab Mouse NGX, for the discovery of human antibody drugs
Release time:2025-12-16
This antibody can effectively combat the A and B subtypes of RSV and reveal its unique epitope of action, providing insights for the development of next-generation RSV therapies
Related news
-
HJCC has released its next-generation genetically modified mouse platform, AlivaMab Mouse NGX, for the discovery of human antibody drugs2025.12.16Learn More
-
HJCC has released its next-generation genetically modified mouse platform, AlivaMab Mouse NGX, for the discovery of human antibody drugs2025.12.16
Learn More